Thermostable Antimicrobial Lipid Formulation via mPEG Solubilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Antimicrobial lipids like glycerol monocaprate and propylene glycol monocaprate have limited water-solubility, leading to precipitation at low temperatures, making it difficult to maintain a clinically effective dose at mucosal surfaces without causing discomfort or loss of the active substance.
Innovation Solution
Formulations incorporating methoxypolyethylene glycol (mPEG) and polyoxyethylene-glycerides are used to create stable, bioadhesive compositions that keep antimicrobial lipids dissolved across a wide temperature range, ensuring effective delivery and prolonged action at mucosal surfaces.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antimicrobial lipids are dissolved in water to achieve clinically effective doses, then the concentration of active substance can be sufficient, but precipitation occurs at low temperatures below 10°C
Solution Approach 1:
The patent introduces solubilizing agents (surfactants, co-solvents, or cyclodextrins) as intermediary substances that mediate between the hydrophobic antimicrobial lipid and hydrophilic aqueous environment. These intermediaries form micelles, complexes, or mixed vehicles that keep the lipid dissolved across a wide temperature range (4°C to 35°C) without precipitation, resolving the contradiction between maintaining high concentration and ensuring temperature stability.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the formulation system by adjusting pH, ionic strength, and temperature conditions to optimize solubility. It also changes the molecular state of the lipid through esterification or salt formation, and adjusts the concentration ratios of lipid to solubilizing agent to maintain dissolution across varying temperatures, thereby preventing precipitation while preserving clinical efficacy.
2Ease of operation
If the volume of formulation is reduced to deliver effective dose to mucosal surfaces, then patient comfort is improved, but the amount of active substance that can be dissolved becomes insufficient
Solution Approach 1:
The patent creates highly concentrated stock solutions or pre-formulated cartridges containing maximum soluble concentrations of antimicrobial lipid stabilized with solubilizing agents. These compact formulations serve as 'copies' or concentrated reservoirs that can be delivered in small volumes (e.g., 1-5 mL) to mucosal surfaces, maintaining both patient comfort and sufficient active substance delivery through optimized solubility enhancement.
3Reliability
If antibiotics are used to treat infections, then bacterial infections can be effectively fought, but resistance generation becomes a risk
Solution Approach 1:
The patent employs antimicrobial lipids (fatty acids, glycerides, or their salts) as alternative antimicrobial agents that act rapidly and locally at infection sites. These lipid-based substances disrupt microbial membranes and provide immediate therapeutic effect without the resistance-generation problem associated with conventional antibiotics. The formulations are designed for localized delivery to mucosal surfaces, providing effective infection control through a different mechanism that avoids long-term resistance development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations maintain stability and bioavailability of antimicrobial lipids at temperatures from 4°C to 35°C, preventing precipitation and ensuring prolonged action at mucosal surfaces, enhancing the efficacy against various pathogens without causing irritation.
Implementation Method 1
Formulations incorporating methoxypolyethylene glycol (mPEG) and polyoxyethylene-glycerides are used to create stable, bioadhesive compositions that keep antimicrobial lipids dissolved across a wide temperature range
Implementation Method 2
The formulations maintain stability and bioavailability of antimicrobial lipids at temperatures from 4°C to 35°C, preventing precipitation
Data Source
AI summary
A formulation to be used for administering a therapeutically effective amount of an antimicrobiologically active monoglyceride to a mammal including administering a pharmaceutical composition having a total volume of 1-5000 μL to a surface of the mammal such as the nasal, ocular, otal, pharynx, larynx, sinuses, oral cavity, vaginal or dermal surface, the pharmaceutical composition including the therapeutically effective amount of the antimicrobiologically active monoglyceride dissolved or suspended in a volume of 1-5000 μL of an methoxypolyethylene glycol referred to as mPEG and polyoxyethylene glycol (PEG)-fatty acid mono- or diglyceride so that upon administration of the pharmaceutical composition to the surface the formulation expresses thermostability within the range from below zero degrees C. to above 35-40° C. and thereby allows the antimicrobiologically active monoglyceride to exert its therapeutic effect.